NPC Spotlight Education Panel Discussion

National Pharmaceutical Counsel sponsored Spotlight Education Panel Discussion on Oct 2, 2024 with Sarah Edmond, President and CEO. This discussion highlighted CMS' growing interest in value and the potential development of a U.S. National HTA.

Quote from Michael Ryan:

"Given the variable and subjective nature of cost utility indices, WTP thresholds, what constitutes value, and how it is calculated and extrapolated, along with the potential concerns of discrimination and delays in access to healthcare that are associated with HTA, there can be little argument that HTA driven QALY assessments are a lower hierarchical science, far lower than systematic reviews, RCTs, and even observational trials. Hence, the U.S. should move cautiously and should not implement a mandatory national HTA until it can ensure that the many limitations of HTA are adequately addressed."